PAUL FEUERSTADT, MD, FACG, AGAF

Paul Feuerstadt, MD, discuses the treatment’s overall safety and efficacy profile and provides insights on data around smaller subsets of patients with comorbidities.

Paul Feuerstadt, MD, FACG, AGAF, discusses what the data says as well as offers insights about what patients can expect and medical peer-to-peer information about the procedure.

The updated guidelines recommend targeting those with active infection and avoiding treatment of “carriers” of C difficile who are colonized but not symptomatic.